Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

ASTRO updates guideline on radiation therapy for pancreatic cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an early-phase trial of patients with advanced pancreatic cancer. The study, led by Cedars-Sinai Health Sciences University investigators, was published in Nature Cancer.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

A new form of proton therapy designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects, is now being tested in a phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

September 11, 2026

Vol.52 No.33

Podcast

As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer

Last month, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

September 09, 2026

Podcast

Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field

On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

September 02, 2026

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

YOU MAY BE INTERESTED IN

ASTRO updates guideline on radiation therapy for pancreatic cancer

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer

Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field

Renew today!

Subscriber content

Never miss an issue!

Login